US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Diabetes · Congenital Bleeding Disorder
Novo Nordisk A/S
Novo Nordisk A/S drug portfolio — 46 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Novo Alle, Bagsværd, 2880, DK HQ
1923 Founded
63,033 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Novo Alle, Bagsværd, 2880, DK
- Founded
- 1923
- Employees
- 63,033
- Programs
- 40
- Drugs
- 46
- Patents
- 0
Novo Nordisk A/S pipeline
Portfolio lens on 46 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Novo Nordisk A/S drug portfolio — 46 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
albutrepenonacog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor IX.
- Target
- Coagulation factor IX
- Mechanism
- Coagulation factor IX exogenous protein
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Novo Nordisk A/S's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-t)
Antineoplastic and immunomodulating agents (L03)Antineoplastic and immunomodulating agents (L03) compound in Novo Nordisk A/S's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
concizumab
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Tissue factor pathway inhibitor.
- Target
- Tissue factor pathway inhibitor
- Mechanism
- Tissue factor pathway inhibitor inhibitor
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
eptacog alfa (activated)
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor VII.
- Target
- Coagulation factor VII
- Mechanism
- Coagulation factor VII exogenous protein
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin degludec
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
insulin detemir
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
insulin icodec
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
liraglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
nonacog beta pegol
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor IX.
- Target
- Coagulation factor IX
- Mechanism
- Coagulation factor IX exogenous protein
-
octocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
rosiglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Novo Nordisk A/S's portfolio. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
somapacitan
Systemic hormonal preparations (H01)Systemic hormonal preparations (H01) compound in Novo Nordisk A/S's portfolio. Molecular target: Growth hormone receptor.
- Target
- Growth hormone receptor
- Mechanism
- Growth hormone receptor agonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
telmisartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
turoctocog alfa
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
turoctocog alfa pegol
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Novo Nordisk A/S's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
Development asset linked to Novo Nordisk A/S in public FDA and regional records.